Coronavirus disease 2019 (COVID- 19) is a novel coronavirus that has spread rapidly across the globe and on the 12th March 2020, the World Health Organisation declared the outbreak a global pandemic ¹ . The current data suggests the mortality rate from COVID-19 is 2–5% ² . The spectrum of disease severity varies, with 14% suffering severe disease and 5% experiencing critical disease, defined as respiratory failure with shock or multi-organ dysfunction ³ . Respiratory failure is often the result of acute respiratory distress syndrome (ARDS) ⁴ . The current literature on the histopathological changes associated with COVID-19 infection is limited to ten cases and diffuse alveolar damage (DAD) is consistently reported as the primary abnormality ^{5– 9} .

We present the case of a 65-year-old female who died in the community amid the COVID-19 pandemic. The aim of this report is contribute to the limited data available on the pathological findings in COVID-19 cases and to highlight the challenge of ascertaining virological PCR confirmation in those patients who have died.

A 65-year-old Caucasian female cleaner with a background of chronic kidney disease and morbid obesity contacted her GP regarding a short history of dry cough and a sore throat. Her GP prescribed antibiotics and advised the patient to self-isolate in line with the NHS COVID-19 guidance. The following day she was discovered deceased at her home address.

The Coroner requested a post mortem examination. External examination of the body confirmed morbid obesity (BMI 49.6kg/m ²). There was no evidence of recent injury. On internal examination, the most striking abnormality was the appearance of the lungs, which were heavy (combined weight 1658g) and diffusely firm ( Figure 1). No pus was expressed from the cut surface. The air passages contained frothy oedema and there was mild reddening of the mucosae. Additionally, there was cardiomegaly (heart weight: 524g) and both ventricles appeared dilated. Scattered, coarse scars were present across the renal surfaces. Internal examination showed no other significant abnormality.

Histology of the lungs showed diffuse hyaline membrane formation, typical of DAD. In areas, narrow hyaline membranes lined the alveolar sacs; elsewhere, these changes were more severe ( Figure 2 and Figure 3). There was prominent pulmonary oedema and variable congestion of the alveolar septal capillaries ( Figure 4). Focally there was an increase in interstitial chronic inflammatory cells and there was type II pneumocyte hyperplasia ( Figure 5 and Figure 6). In areas, the bronchiolar epithelium appeared attenuated with possible ulceration, indicating larger airway involvement ( Figure 7). No viral inclusion bodies or multinucleated giant cells were seen.

Histology of the heart, brain, spleen, thyroid and tonsils were normal. Sections taken from the kidneys revealed mild glomerulosclerosis. The liver showed mild fatty change. Unfortunately, in certain parts of the UK, laboratories are not processing virology samples in patients who have already died and therefore virological confirmation was not available. The cause of death was offered as COVID-19 based on the history and histopathological findings.

This case report describes the autopsy findings in an individual who died in the community whilst isolating with symptoms of COVID-19. The current literature on post mortem findings in cases of COVID-19 infection is limited, but the available data consistently highlights DAD as the predominant pathological process. This case report contributes to the growing body of evidence that describes features of DAD in the setting of COVID-19 associated acute respiratory symptoms. There is also emerging evidence to suggest some individuals may develop cardiovascular complications due to COVID-19 infection ^{10– 12} . In this case, the heart was enlarged but histology was normal and these changes most likely represent obesity-related cardiomegaly.

The absence of post mortem virology testing is a limitation in this case. Considering the consistent symptomology and amidst the current pandemic, the histopathological changes were considered diagnostic for COVID-19. Availability and sensitivity of testing seem varied across the UK. In some regions, autopsy examinations are delayed whilst awaiting results from post mortem nasal swabs; an invasive examination is only carried out if these results are negative. Interestingly, in the recent case published by Barton LM et al., ⁹ nasal swabs were positive for COVID-19 but pulmonary swabs were negative and post mortem examination revealed bronchopneumonia as the cause of death, suggesting post mortem nasopharyngeal swabs may not be an accurate screening method after death. Based on the data available, it appears that lung histology provides the most reliable means to attribute death to COVID-19 infection, providing the clinical history is appropriate. It is worth noting that currently in the UK, suspected COVID cases in the community are not able to access confirmatory swabbing and so the onus will often fall to the pathologists to establish an appropriate cause of death. From anecdotal hospital experience, patients who develop COVID-19 associated ARDS will often succumb rapidly following a dramatic increase in oxygen requirements over a period of several hours (Johnson O, personal communication, 14 Apr 2020). For this reason, the authors are aware that the number of community deaths will inevitably continue to increase given that some patients may not be able to get to secondary care in a timely fashion.

At our centre, invasive autopsies in cases of suspected COVID-19 infection are now only performed when the history indicates a probable alternative to the cause of death, or where there are concerns that the death may be suspicious. When it seems that death has resulted from respiratory failure, post mortems are limited to an external examination for the purposes of ruling out unnatural causes. Providing there are no unexpected or suspicious findings, a cause of death is offered based on a history consistent with COVID-19 infection. Whilst there are many benefits to an invasive autopsy, such as facilitating accurate diagnosis, excluding internal trauma and improving understanding of the disease, factors such as accessibility of COVID-19 testing, availability of personal protective equipment, infection risk to staff and body storage capacity must be considered. Where COVID-19 is suspected, the appropriateness of performing an invasive procedure must be decided on a case-by-case basis.

Written informed consent for publication of their clinical details and clinical images was obtained from the next of kin of the patient.

All data underlying the results are available as part of the article and no additional source data are required.